TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07725380: Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 74 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07725380 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07725380 Rescue Dossier →